Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FBT-N401
- Development stage
- Preclinical
- Lead developer
- Fusion Biotechnology
- Modality
- Small Molecules
01
Overview
FBT-N401 is a small-molecule Yes-associated protein 1 (YAP) activator being developed by Fusion Biotechnology (FusionBioTech) for the treatment of dry and wet age-related macular degeneration (AMD). YAP is a key transcriptional co-activator and mechanotransducer in the Hippo signaling pathway that plays a critical role in maintaining retinal pigment epithelium (RPE) cell survival and function. Impaired cell-matrix adhesion in aging RPE cells leads to YAP inactivation and subsequent cellular senescence, contributing to AMD pathogenesis. By activating YAP, FBT-N401 aims to reverse RPE senescence, promote cell survival, and restore visual function. The therapeutic candidate is currently in the research stage of development.
02
Targets
YAP1 (YES-associated protein–transcriptional enhancer factor domain complex)
Beyond the preview
Go deeper on FBT-N401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FBT-N401.